Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Adverio Pharma Gmbh

Boehringer Ingelheim International Gmbh

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Axxam S.p.a.

Bayer Aktiengeselischaft

Bayer Schering Pharma Aktiengellschaft

Frank Wunder

Johannes-Peter Stasch

Andreas Knorr

Volkhart Min-Jian Li

Gorden Redlich

Markus Follmann

Karl-Heinz Schlemmer

Dieter Lang

Michael Hahn

Alexandros Vakalopoulos

Nils Griebenow

Eva-Maria Becker

Elke Stahl

Rolf Jautelat

Joachim Mittendorf

Niels Lindner

Jens Ackerstaff

Cristina Alonso-Alija

Klaus Dembowsky

Friederike Stoll

Philipp Buchgraber

Dietmar Flubacher

Eva Maria Becker-Pelster

Alexander Straub

Walter Hübsch

Achim Feurer

Elisabeth Perzborn

Thomas Lampe

Hanna Tinel

Ingo Hartung

Tobias Marquardt

Stefan Weigand

Damian Brockschnieder

Walter Kroh

Lisa Dietz

Donald Bierer

Elke Hartmann

Alexey Gromov

Adrian Tersteegen

Carsten Schmeck

Raimund Kast

Dirk Schneider

Markus Heil

Anja Buchmüller

Paul Naab

Claudia Hirth-Dietrich

Michael Härter

Sherif El Sheikh

Karen Engel

Elisabeth Woltering

Jorma Haβfeld

Herbert Himmel

Andreas Göller

Thomas Rölle

Wahed Ahmed Moradi

Josef Pernerstorfer

Joerg Keldenich

Johannes Köbberling

Stephan Bartel

Volker Geiss

Rudolf Schohe-Loop

Hans-Georg Lerchen

Martin Hendrix

Christina Erb

Lars Bärfacker

Joachim Luithle

Marja Van Kampen

Stefan Heitmeier

Martina Delbeck

Ingo Flamme

Hartmut Schirok

Rudy Schreiber

Klaus Münter

Sven Wittrock

Ildiko Terebesi

Maria Köllnberger

Gerhard König

Stephan-Nicholas Wirtz

Eva-Maria Becker-Pelster

René Martin

Julie Marley

Peter Kolkhof

Jan Tebbe

Thomas Mondritzki

Frank-Gerhard Böss

Thomas Schenke

Joachim Schuhmacher

Frank-Gerhard Böβ

Simone Greven

Chantal Fürstner

Gunter Karig

Haruka Shimizu

Christoph Mahlert

Holger Paulsen

Timo Stellfeld

Ernst Weber

Peter Sandner

Christian Pilger

Jorma Hassfeld

Arnel B Concepcion

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Brain natriuretic peptide engrafted antibodies

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Atrial natriuretic peptide engrafted antibodies

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Substituted pyrazolo piperidine carboxylic acids

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted 5-fluoro-1H-pyrazolopyridines and their use

The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

Branched 3-phenylpropionic acid derivatives and their use

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

Substituted piperidinyl tetrahydroquinolines

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use

The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Heteroaryl-substituted imidazo[1,2-A]pyridines and their use

The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof

The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-A]pyridines and their use

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases

Growing community of inventors

Wuppertal, Germany

Frank Wunder